前列腺特异抗原及其密度测定在前列腺癌

为探讨前列腺特异抗原（PSA）及前列腺特异抗原密度（PSAD）的临床应用价值，用放射免疫分析法测定了28例前列腺癌（Pca)及80例良性前列腺增生（BPH）患者的治疗前，后PSA含量，其中18例Pca及50例BPH患者同时测定了PSAD，结果PSA诊断Pca的灵敏度，特异性和准确度分别为85．7％，80．0％和81．4％，在鉴别Pca和BPH上PSAD优于PSA，使假阳性率由PSA的20％降到6％，但在临床应用中要注意结合其它检查进行综合分析。治疗后定期检测血清PSA对早期发现局部复发或转移，判断疗效和估测预后均有重要价值。

The Value of Prostate Specific Antigen and Prostate Specific Antigen Density in the Diagnosis and Treatment of Prostate Cancer

To study the clinical value of prostate specific antigen(PSA) and prostate specific antigen density(PSAD), the PSA levels of pre-and post-treatment were measured in 28 cases with prostate cancer(Pca) and 80 patients with benign Prostate hyperplasia(BPH). PASD was measared in 18 cases Pca and 50 cases BPH of them. The results suggest that the sensibility, specificity and accuracy of diagnosis for Pca were 85.7%, 80.0% and 81.4%, respectively. The false positive rate was 20%. PSAD is superior to PSA in distinguishing prostate cancer from benign prostate hyperplasia. The false positive rate was only 6%. But in the clinical application, we should combine PASD with other materials. The regular observation of post therapeutic PSA is of great value to the earlier discovery of local recurrence and metastasis as well as the judgement of curative effect and prognosis.